AR121404A1 - Uso de análogos de ciclosporina para tratar cáncer - Google Patents

Uso de análogos de ciclosporina para tratar cáncer

Info

Publication number
AR121404A1
AR121404A1 ARP210100463A ARP210100463A AR121404A1 AR 121404 A1 AR121404 A1 AR 121404A1 AR P210100463 A ARP210100463 A AR P210100463A AR P210100463 A ARP210100463 A AR P210100463A AR 121404 A1 AR121404 A1 AR 121404A1
Authority
AR
Argentina
Prior art keywords
treat cancer
cyclosporine analogs
crv431
stereoisomer
solvate
Prior art date
Application number
ARP210100463A
Other languages
English (en)
Inventor
Daren Raymond Ure
Daniel Joseph Trepanier
Patrick R Mayo
Robert Thomas Foster
Original Assignee
Hepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepion Pharmaceuticals Inc filed Critical Hepion Pharmaceuticals Inc
Publication of AR121404A1 publication Critical patent/AR121404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente métodos, composiciones y kits adecuados para uso en la prevención y tratamiento de enfermedades proliferativas tales como cáncer. Los métodos comprenden administrar a un sujeto que lo necesita una composición que comprende un análogo de ciclosporina (por ej. CRV431) o una sal, solvato, estereoisómero del mismo farmacéuticamente aceptables. Las composiciones y kits comprenden un análogo de ciclosporina (por ej. CRV431) o una sal, solvato, estereoisómero del mismo farmacéuticamente aceptables.
ARP210100463A 2020-02-25 2021-02-24 Uso de análogos de ciclosporina para tratar cáncer AR121404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062981383P 2020-02-25 2020-02-25

Publications (1)

Publication Number Publication Date
AR121404A1 true AR121404A1 (es) 2022-06-01

Family

ID=74885085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100463A AR121404A1 (es) 2020-02-25 2021-02-24 Uso de análogos de ciclosporina para tratar cáncer

Country Status (13)

Country Link
US (1) US20210269479A1 (es)
EP (1) EP4110346A1 (es)
JP (1) JP2023515569A (es)
KR (1) KR20220145849A (es)
CN (1) CN115484961A (es)
AR (1) AR121404A1 (es)
AU (1) AU2021227230A1 (es)
BR (1) BR112022016960A2 (es)
CA (1) CA3172368A1 (es)
IL (1) IL295498A (es)
MX (1) MX2022010454A (es)
TW (1) TW202140057A (es)
WO (1) WO2021173723A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308149T3 (es) * 2003-02-12 2008-12-01 Biocompatibles Uk Limited Composicion para la quimioemboloterapia de tumores solidos.
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
ES2858517T3 (es) * 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Composiciones que comprenden ciclosporina
CA3024320A1 (en) * 2016-05-17 2017-11-23 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
WO2018106928A1 (en) * 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US20180296588A1 (en) * 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
SI3886813T1 (sl) 2018-11-26 2023-05-31 Hepion Pharmaceuticals, Inc. Farmacevtske formulacije analogov ciklosporina

Also Published As

Publication number Publication date
TW202140057A (zh) 2021-11-01
IL295498A (en) 2022-10-01
MX2022010454A (es) 2022-09-19
AU2021227230A1 (en) 2022-09-08
KR20220145849A (ko) 2022-10-31
WO2021173723A8 (en) 2022-08-25
US20210269479A1 (en) 2021-09-02
BR112022016960A2 (pt) 2022-10-25
JP2023515569A (ja) 2023-04-13
CN115484961A (zh) 2022-12-16
WO2021173723A1 (en) 2021-09-02
EP4110346A1 (en) 2023-01-04
CA3172368A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
CO2020004906A2 (es) Composiciones y métodos para la eliminación de células cd117+
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CR20180494A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
CL2022003143A1 (es) Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos (divisional solicitud patente 202102780)
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
CL2019000778A1 (es) Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso.
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
CO2019003894A2 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
AR121404A1 (es) Uso de análogos de ciclosporina para tratar cáncer
CO2018011797A2 (es) Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CL2022001079A1 (es) Métodos y composiciones para el tratamiento del síndrome de rett
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia